We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cell-based Gene Therapy Treatment Cures Hemophilia B in Model

By LabMedica International staff writers
Posted on 17 May 2018
Print article
Image: Left two panels: Hepatocyte-like cells (HLCs) differentiated from the stem cells of patients with hemophilia B show very low levels of clotting factor IX, (FIX), shown in white. Right two panels: After treating these same cell lines with a gene correction tool, FIX increased to healthy levels (Photo courtesy of the Salk Institute).
Image: Left two panels: Hepatocyte-like cells (HLCs) differentiated from the stem cells of patients with hemophilia B show very low levels of clotting factor IX, (FIX), shown in white. Right two panels: After treating these same cell lines with a gene correction tool, FIX increased to healthy levels (Photo courtesy of the Salk Institute).
A novel, cell-based gene therapy approach was used to cure hemophilia B in a mouse model of the disease.

Hemophilia B, a blood-clotting disorder caused by defects in the gene encoding the protein-clotting factor IX (FIX) is considered to be an appropriate target for gene- and cell-based therapies due to its monogenic nature and broad therapeutic index.

Toward this end, investigators at the Salk Institute (La Jolla, CA, USA) used their FIX-deficient mouse model to evaluate the use of cell therapy as a potential long-term cure for hemophilia B. Initially, they showed that transplanted, cryopreserved, cadaveric human hepatocytes remained functional for more than a year and secreted FIX at therapeutic levels. Hepatocytes from different sources (companies and donors) performed comparably in curing the bleeding defect.

Next, the investigators generated induced pluripotent stem cells (iPSCs) from two hemophilia B patients and used the CRISPR/Cas9 gene-editing tool to correct the disease-causing mutations. These corrected iPSCs were coaxed into differentiating into hepatocyte-like cells (HLCs) and were then transplanted into hemophilic mice.

Results published in the May 1, 2018, online edition of the journal Cell Reports revealed that the transplanted iPSC-HLCs produced enough FIX to enable the mice to form normal blood clots, and that the cells continued to survive and produce FIX for at least nine to 12 months.

"The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs," said first author Dr. Suvasini Ramaswamy, a former research associate at the Salk Institute. "Rather than constant injections, you can do this in one shot."

Related Links:
Salk Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.